RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17

Published on 10/16/2026 at 03:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The October 15, 2026 deal pairs RxSight's adjustable lens technology with Alcon's designs. Twelve firms assign RxSight stock a USD 8.17 consensus target.

Collaboration and financial pressure

RxSight and Alcon agreed on a collaboration worth up to USD 200 million on October 15, 2026.
Second-quarter revenue reached USD 33.7 million, while product sales totaled USD 27.2 million.
Twelve firms assign RxSight a USD 8.17 consensus target.
MarketBeat estimates the next results date as November 4, 2026.
RxSight had a USD 194.2 million market capitalization as of October 15, 2026.

RXST, US78349D1072, Illustration mit AI erstellt.

RxSight (ISIN US78349D1072) and Alcon announced a non-exclusive collaboration on October 15, 2026, to develop adjustable presbyopia-correcting intraocular lenses with up to USD 200 million in upfront and milestone payments, according to Latham and Watkins. The agreement combines RxSight's post-operative light-adjustable technology with Alcon's optical designs.

What does the Alcon deal add?

The collaboration gives RxSight a route into presbyopia-correcting lenses while its existing platform remains centered on cataract surgery. The company recognized USD 6.5 million of collaboration revenue in the second quarter of 2026, and its June 30, 2026 balance sheet included USD 208.8 million in cash, cash equivalents and short-term investments, according to RxSight.

Why margins still matter

RxSight reported USD 33.7 million of revenue in the second quarter of 2026, including the Alcon contribution, compared with USD 33.6 million in the year-ago quarter. Product sales fell 19 percent year over year to USD 27.2 million, while gross margin excluding collaboration revenue declined to 71.2 percent from 74.9 percent, according to RxSight. The company posted a GAAP net loss of USD 12.1 million, or USD 0.29 per diluted share, for that period.

Analyst sentiment remains cautious. MarketBeat reported on October 3, 2026, that twelve firms assigned an average Reduce rating and a USD 8.17 12-month target. The group included three sell ratings, seven hold ratings and two buy ratings.

When does RxSight report again?

MarketBeat estimates that RxSight will report third-quarter 2026 results on November 4, 2026, after the market closes. The estimate puts the next report at the center of the debate over product demand, collaboration revenue and operating costs.

Stock valuation and next catalyst

RxSight's latest Nasdaq quote was USD 4.67 on October 15, 2026 at 4:00 p.m. ET. The stock had a USD 194.2 million market capitalization and a 52-week range of USD 4.40 to USD 16.74 as of that date. The next reported figures will show whether the Alcon collaboration can offset weaker product sales.